表紙
市場調查報告書

皮膚科治療藥的全球市場的預測 - 2020年∼2030年:乾癬,皮膚感染,粉刺,皮膚炎

Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others

出版商 Visiongain Ltd 商品編碼 233143
出版日期 內容資訊 英文 355 Pages
商品交期: 最快1-2個工作天內
價格
皮膚科治療藥的全球市場的預測 - 2020年∼2030年:乾癬,皮膚感染,粉刺,皮膚炎 Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others
出版日期: 2019年10月31日內容資訊: 英文 355 Pages
簡介

全球皮膚科治療藥市場,2018年達到310億美元,預計今後5年以3.7%的年複合成長率成長。

本報告提供全球皮膚科治療藥市場相關調查分析,詳細市場分析,主要促進因素、課題,主要企業等相關的系統性資訊。

第1章 報告概要

第2章 皮膚科治療藥的簡介

  • 製藥產業:概要
  • 皮膚科的簡介
  • 一般皮膚病
  • 皮膚感染
  • 一般皮膚治療
  • 臨床實驗階段
  • 市場定義

第3章 全球皮膚科治療藥市場:各適應症

  • 市場概要
  • 類別化
  • 市場成果
  • 市場預測
  • 市場佔有率的變化:各市場區隔

第4章 乾癬治療藥市場:市場分析、預測

  • 乾癬治療:生技藥品的優勢
  • 乾癬:市場趨勢、發展
  • 乾癬治療藥:市場預測
  • 乾癬的治療所使用的主要藥
    • Humira (adalimumab)
    • Stelara (ustekinumab)
    • Enbrel (etanercept)
    • Remicade (infliximab)
    • Taltz (ixekizumab)等

第5章 皮膚感染治療藥市場:市場分析、預測

  • 皮膚感染治療藥:豐富的成長機會
  • 皮膚感染治療藥:市場預測
  • 皮膚感染的治療所使用的主要藥
    • Zyvox (linezolid)
    • Canesten (clotrimazole)
    • Valtrex (valaciclovir)
    • Sivexto
    • Lamisil (terbinafine)等

第6章 粉刺治療藥市場:市場分析、預測

  • 粉刺治療藥:多樣化的市場
  • 粉刺治療藥市場:最近的趨勢、發展
  • 粉刺治療藥:市場預測
  • 粉刺治療藥市場上主要藥
  • 粉刺治療藥:市場摘要
    • Epiduo (adapalene/benzoyl peroxide)
    • Solodyn (minocycline)
    • Claravis (isotretinoin)
    • Aczone (dapsone)
    • Retin-A Micro等

第7章 皮膚炎治療藥市場:市場分析、預測

  • 皮膚炎治療藥:非專利的普及率高
  • 皮膚炎治療藥:市場預測
  • 皮膚炎治療藥市場上主要藥
  • 皮膚炎治療藥:市場預測
    • Bepanthen (dexpanthenol)/Bepanthol
    • Elocon (mometasone)
    • Protopic (tacrolimus)
    • Dermovate等

第8章 主要國家市場

  • 各地區明細
  • 各地區預測

第9章 北美的皮膚科治療藥市場

  • 美國
  • 加拿大

第10章 歐洲的皮膚科治療藥市場

  • 市場佔有率的變化:各國
  • 德國
  • 英國
  • 義大利
  • 西班牙
  • 其他

第11章 亞太地區的皮膚科治療藥市場

  • 中國
  • 日本
  • 印度
  • 其他

第12章 南美的皮膚科治療藥市場

  • 巴西
  • 墨西哥
  • 其他

第13章 中東、非洲的皮膚科治療藥市場

  • 沙烏地阿拉伯
  • 南非
  • 其他

第14章 皮膚科治療藥市場上主要企業

  • Galderma (Nestle Skin Health S.A.)
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • LEO Pharma A/S
  • AbbVie Inc.
  • Novartis AG
  • Amgen, Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Celgene Corporation
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Allergan plc
  • Eli Lilly and Company

第15章 皮膚科治療藥:R&D (研究開發) 開發平台

第16章 皮膚科治療藥市場定性分析

第17章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0577

The revenue of the dermatological drugs market in 2018 is estimated at $31bn and is expected to grow at a CAGR of 3.7% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2018, this segment accounted for 38% of the global dermatological drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 355-page report you will receive 133 tables and 154 figures - all unavailable elsewhere.

The 355-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Dermatological drugs market forecasts from 2020-2030

This report also breaks down the revenue forecast for the main submarkets:

  • Psoriasis
  • Skin Infections
  • Acne
  • Dermatitis

Analysis of the Psoriasis drugs market. Revenue forecasts to 2030 are provided for the following drugs:

  • Humira
  • Stelara
  • Enbrel
  • Remicade
  • Taltz
  • Otezla
  • Cosentyx

Analysis of the Skin Infections drugs market. Revenue forecasts to 2030 are provided for the following drugs:

  • Cubicin
  • Zyvox
  • Valtrex
  • Canesten
  • Lamisil
  • Bactroban

Analysis of the Acne drugs market. Revenue forecasts to 2030 are provided for the following drugs:

  • Solodyn
  • Epiduo
  • Claravis
  • Aczone
  • Differin
  • Abscorical/Epirus
  • Ziana
  • Doryx

Analysis of the Dermatitis drugs market. Revenue forecasts to 2030 are provided for the following drugs:

  • Bepanthen/Bepanthol
  • Protopic
  • Dermovate
  • Elocon

This report provides individual revenue forecasts to 2030 for these regional and national markets:

  • North America: US & Canada
  • Europe: Germany, France, UK, Italy, Spain, Rest of Europe
  • Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.

This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.

Our study discusses the selected leading companies that are the major players in the dermatological drugs market:

  • AbbVie
  • Allergan
  • Amgen
  • Bausch Health
  • Bayer AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly
  • Galderma (Nestle Skin Health S.A.)
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • LEO Pharma
  • Merck & Co, Inc.
  • Novartis
  • Pfizer

Key questions answered by this report:

  • How is the dermatological drugs market evolving?
  • What is driving and restraining the dermatological drugs market?
  • What are the market shares of each segment of the overall dermatological drugs market in 2019?
  • How will each dermatological drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each dermatological drugs submarket develop from 2020 to 2030?
  • Which individual therapies will prevail and how will these shifts be responded to?
  • What will be the main driver for the overall market from 2020 to 2030?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Will leading national dermatological drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2019 and 2030?

Visiongain understands that the dermatological drugs market will register strong growth. This report examines in detail the market by region, by submarket, and as a whole, and provides the reader with a thorough overview of the market to identify key growth areas and business opportunities to exploit. This is where Visiongain adds value.

Visiongain's study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Buy our report today Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Dermatological Drugs Market Overview
  • 1.2. Overview of Findings
  • 1.3. Structure of the Report
  • 1.4. Global Dermatological Drugs Market Segmentation
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction to Dermatological Drugs

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
  • 2.2. An Introduction to Dermatology
    • 2.2.1. The Structure of Skin, Hair, and Nails
    • 2.2.2. Hair and Nails
    • 2.2.3. Sweat and Sebaceous Glands
    • 2.2.4. Functions of the Skin
  • 2.3. Common Skin Diseases
    • 2.3.1. Acne: The Most Common Skin Disease
      • 2.3.1.1. Acne: Epidemiology
      • 2.3.1.2. Acne: Causes and Pathogenesis
      • 2.3.1.3. Acne: Treatment
    • 2.3.2. Dermatitis: Inflammation of the Skin
      • 2.3.2.1. Atopic Dermatitis
      • 2.3.2.2. Contact Dermatitis
      • 2.3.2.3. Seborrhoeic Dermatitis
      • 2.3.2.4. Nummular Dermatitis
      • 2.3.2.5. Perioral Dermatitis
    • 2.3.3. Psoriasis: A Complex Multi-Factorial Disease
    • 2.3.4. Rosacea: Vascular Instability
    • 2.3.5. Alopecia: Excessive Shedding of Hair
  • 2.4. Skin Infections: A Serious Healthcare Threat
    • 2.4.1. Bacterial Skin Infections
    • 2.4.2. Fungal Skin Infections
    • 2.4.3. Viral Skin Infections
  • 2.5. Common Skin Treatments
    • 2.5.1. Creams and Semisolid Emulsions
    • 2.5.2. Ointments
    • 2.5.3. Lotions
    • 2.5.4. Solutions
    • 2.5.5. Occlusive Therapy
    • 2.5.6. Cleansing Agents
    • 2.5.7. Powders and Hydrophilic Polymer
    • 2.5.8. Anti-Infective Agents
    • 2.5.9. Anti-Inflammatory Agents
  • 2.6. Phases of Clinical Trials
  • 2.7. Dermatological Drugs: Market Definition in this Report

3. Global Dermatological Drugs Market by Indication 2020-2030

  • 3.1. The Global Dermatological Drugs Market: Market Overview
  • 3.2. Categorisation of the Global Dermatological Drugs Market
  • 3.3. The Global Dermatological Drugs Market in 2019
  • 3.4. The Global Dermatological Drugs Market: Market Forecast 2020-2030
  • 3.5. Changing Market Shares by Segment 2020-2030

4. The Psoriasis Drugs Market: Market Analysis and Forecast 2020-2030

  • 4.1. Psoriasis Treatments: The Dominance of Biologics
    • 4.1.1. Leading Products in the Psoriasis Drugs Market, 2019
  • 4.2. Psoriasis: Market Trends and Developments, 2019
    • 4.2.1. Biological Drugs in Psoriasis Treatment: A Brief Overview
    • 4.2.2. Issues around Patent Protection, the Threat of Biosimilars and Pricing
    • 4.2.3. Biosimilars and Interchangeables
      • 4.2.3.1. Extrapolation of indications
      • 4.2.3.2. Biosimilar interchangeability in the EU
      • 4.2.3.3. Biosimilar guidance in the US
      • 4.2.3.4. The Disadvantages of Biologics in Psoriasis Treatment
  • 4.3. Psoriasis Drugs: Market Forecast 2020-2030
    • 4.3.1. Psoriasis Drugs: Changing Market Shares by Leading Drugs 2020-2030
  • 4.4. Leading Drugs Used in the Treatment of Psoriasis
    • 4.4.1. Humira (adalimumab) - AbbVie
      • 4.4.1.1. Humira: Historical Sales Analysis, 2010-2017
      • 4.4.1.2. Humira: Sales Forecast 2020-2030
      • 4.4.1.3. Future Prospects for Biosimilar Versions of Humira
    • 4.4.2. Stelara (ustekinumab) - Johnson & Johnson
      • 4.4.2.1. Stelara New Market Leader, Ahead of Humira
      • 4.4.2.2. Stelara: Historical Sales Analysis, 2010-2017
      • 4.4.2.3. Stelara: Sales Forecast 2020-2030
      • 4.4.2.4. Intensifying Competition for Stelara
    • 4.4.3. Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
      • 4.4.3.1. Enbrel: Co-Promotions and Marketing Rights
      • 4.4.3.2. Enbrel: Historical Sales Analysis, 2009-2017
      • 4.4.3.3. Enbrel: Patent Expiries and Potential Competition, 2020-2030
      • 4.4.3.4. Patent Litigation with Sandoz Over Enbrel
      • 4.4.3.5. Enbrel: Sales Forecast 2020-2030
      • 4.4.3.6. Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
      • 4.4.3.7. Competition from Other Drugs
      • 4.4.3.8. Biosimilar Competition for Enbrel
    • 4.4.4. Remicade (infliximab) - Johnson & Johnson
      • 4.4.4.1. Remicade: Historical Sales Analysis, 2009-2017
      • 4.4.4.2. Remicade: Patent Expiries and Potential Competition, 2020-2030
      • 4.4.4.3. Remicade: Sales Forecast 2020-2030
    • 4.4.5. Taltz (ixekizumab) - Eli Lilly
      • 4.4.5.1. Taltz: Sales Forecast 2020-2030
    • 4.4.6. Otezla (apremilast) - Celgene
      • 4.4.6.1. Otezla: Sales Forecast 2020-2030
    • 4.4.7. Cosentyx (secukinumab) - Novartis
      • 4.4.7.1. Cosentyx: Sales Forecast 2020-2030
    • 4.4.8. Other Psoriasis Drugs
      • 4.4.8.1. Cimzia (certolizumab) - UCB
      • 4.4.8.2. Sorilux (calcipotriene foam) - GSK
      • 4.4.8.3. Siliq (brodalumab) - AstraZeneca/ LEO Pharma
      • 4.4.8.4. Other Psoriasis Drugs: Sales Forecast 2020-2030
  • 4.5. Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis and Forecast 2020-2030

  • 5.1. Skin Infection Drugs: Abundant Growth Opportunities
    • 5.1.1. Leading Products in the Skin Infection Drugs Market, 2019
  • 5.2. Skin Infection Drugs: Market Forecast 2020-2030
    • 5.2.1. Skin Infection: Changing Market Shares by Leading Drugs 2020-2030
  • 5.3. Leading Drugs Used in the Treatment of Skin Infections
    • 5.3.1. Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
    • 5.3.2. Acquisition by Merck & Co
    • 5.3.3. Generic Competition for Cubicin
    • 5.3.4. Cubicin: Sales Forecast 2020-2030
    • 5.3.5. Lifecycle Management Strategies for Cubicin
  • 5.4. Zyvox (linezolid) - Pfizer
    • 5.4.1. Zyvox: Historical Sales Analysis, 2010-2017
    • 5.4.2. Zyvox: Sales Forecast 2020-2030
    • 5.4.3. The Threats to Zyvox Sales from Competing New Drugs
  • 5.5. Canesten (clotrimazole) - Bayer
    • 5.5.1. Canesten: Historical Sales Analysis, 2011-2017
    • 5.5.2. Canesten: Sales Forecast 2020-2030
  • 5.6. Valtrex (valaciclovir) - GSK
    • 5.6.1. Valtrex: Historical Sales Analysis, 2010-2017
    • 5.6.2. Valtrex: Sales Forecast 2020-2030
  • 5.7. Sivexto
    • 5.7.1. Sivexto: Sales Forecast 2020-2030
  • 5.8. Lamisil (terbinafine) - Novartis
    • 5.8.1. Lamisil Patent Expiry
    • 5.8.2. Lamisil Sales Affected by Novartis Manufacturing Problems
    • 5.8.3. Lamisil: Sales Forecast 2020-2030
  • 5.9. Other Skin Infection Drugs
    • 5.9.1. Dalvance (dalbavancin) - Durata Therapeutics
    • 5.9.2. Jublia (efinaconazole) - Valeant
    • 5.9.3. Kerydin (tavaborole) - Anacor
    • 5.9.4. Zovirax (acyclovir) - Valeant/GSK
      • 5.9.4.1. Valeant Acquires Zovirax in US and Canada
      • 5.9.4.2. Mylan's Generic Zovirax and Actavis' Authorised Generic
    • 5.9.5. Other Skin Infection Drugs: Sales Forecast 2020-2030
  • 5.10. Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis and Forecast 2020-2030

  • 6.1. Acne Drugs: A Diversified Market
    • 6.1.1. Leading Products in the Acne Drugs Market, 2019
  • 6.2. Acne Drugs Market: Recent Trends and Developments
    • 6.2.1. The Rise of Combination Therapies in Acne Treatment
    • 6.2.2. Oral Contraceptives in Treating Acne
    • 6.2.3. The Threat of Generic Competition in the Acne Drugs Market
  • 6.3. Acne Drugs: Market Forecast 2020-2030
    • 6.3.1. Acne Drugs: Changing Market Shares by Leading Drugs 2020-2030
  • 6.4. Leading Drugs in the Acne Drugs Market
    • 6.4.1. Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health
      • 6.4.1.1. Epiduo: Sales Forecast 2020-2030
      • 6.4.1.2. Galderma Settlement Agreement over Generic Epiduo
      • 6.4.1.3. Paediatric Approval for Epiduo
    • 6.4.2. Solodyn (minocycline) - Valeant
      • 6.4.2.1. Solodyn: Sales Forecast 2020-2030
      • 6.4.2.2. Antitrust Action over Solodyn Pay-For-Delay Deals
      • 6.4.2.3. Impax and Medicis Collaborating on Advanced Solodyn
      • 6.4.2.4. Medicis and Lupin Settle
    • 6.4.3. Claravis (isotretinoin) - Teva
      • 6.4.3.1. Claravis: Sales Forecast 2020-2030
    • 6.4.4. Aczone (dapsone) - Allergan
      • 6.4.4.1. Aczone: Sales Forecast 2020-2030
    • 6.4.5. Retin-A Micro - Bausch Health
      • 6.4.5.1. Retin-A Micro: Sales Forecast 2020-2030
    • 6.4.6. Absorica/Epuris (CIP-isotretinoin) - Cipher/Sun Pharma
      • 6.4.6.1. Absorica/Epuris: Sales Forecast 2020-2030
    • 6.4.7. Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
      • 6.4.7.1. Valeant's Patent Settlement with Actavis over Ziana
      • 6.4.7.2. Ziana: Sales Forecast 2020-2030
    • 6.4.8. Acanya (clindamycin/benzoyl peroxide) - Dow /Valeant
      • 6.4.8.1. Actavis Claims First-to-File Exclusivity for its Acanya
      • 6.4.8.2. Legal Battles Involving Dow/Valeant, Perrigo, and
      • 6.4.8.3. Acanya: Sales Forecast 2020-2030
    • 6.4.9. Other Acne Drugs
      • 6.4.9.1. Doryx (doxycycline) - Actavis/Mayne Pharma
        • 6.4.9.1.1. Lifecycle Management Strategies for Doryx
        • 6.4.9.1.2. Divestment Agreement with Mayne Pharma
        • 6.4.9.1.3. Generic Competition for Doryx
      • 6.4.9.2. Amnesteem (isotretinoin) - Mylan
        • 6.4.9.2.1. Amnesteem: Financial Analysis
      • 6.4.9.3. Diane (cyproterone/ethinyl estradiol) - Bayer
      • 6.4.9.4. Duac (clindamycin/benzoyl peroxide) -
      • 6.4.9.5. Veltin (tretinoin/clindamycin) - GSK
      • 6.4.9.6. Other Acne Drugs: Sales Forecast 2020-2030
  • 6.5. Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis and Forecast 2020-2030

  • 7.1. Dermatitis Drugs: High Generic Penetration
    • 7.1.1. Leading Products in the Dermatitis Drugs Market, 2019
  • 7.2. Dermatitis Drugs: Market Forecast 2020-2030
    • 7.2.1. Dermatitis Drugs: Changing Market Shares by Leading Drugs 2020-2030
  • 7.3. Leading Drugs in the Dermatitis Drugs Market
    • 7.3.1. Bepanthen (dexpanthenol)/ Bepanthol - Bayer
      • 7.3.1.1. Bepanthen: Sales Forecast 2020-2030
    • 7.3.2. Elocon (mometasone) - Merck & Co
      • 7.3.2.1. Elocon: Sales Forecast 2020-2030
    • 7.3.3. Protopic (tacrolimus) - LEO Pharma
      • 7.3.3.1. Protopic Benefits from Expanded Indication
      • 7.3.3.2. Generic Competition for Protopic
      • 7.3.3.3. Protopic: Sales Forecast 2020-2030
    • 7.3.4. Dermovate -GSK
      • 7.3.4.1. Dermovate: Sales Forecast 2020-2030
    • 7.3.5. Other Dermatitis Drugs: Sales Forecast 2020-2030
  • 7.4. Dermatitis Drugs: Market Outlook

8.Leading National Markets 2020-2030

  • 8.1. Geographical Breakdown of the World Dermatological Drugs Market
  • 8.2. World Dermatological Drugs Market: Regional Forecast 2020-2030
    • 8.2.1. How Will Regional Market Shares Change to 2030?

9. North America Dermatological Drugs Market 2020-2030

  • 9.1. U.S. Dermatological Drugs Market: Trends and Developments
    • 9.1.1. Obamacare Repeal
    • 9.1.2. Legislative Environment Stimulating Biosimilars
    • 9.1.3. Biosimilar Interchangeability guidance in the US
    • 9.1.4. US Dermatological Drugs Market: Market Forecast 2020-2030
  • 9.2. Canada Dermatological Drugs Market: Trends and Developments

10. Europe Dermatological Drugs Market 2020-2030

  • 10.1. Europe Markets: Changing Market Shares by Country, 2020-2030
  • 10.2. Germany
    • 10.2.1. Germany Dermatological Drugs Market: Market Forecast 2020-2030
  • 10.3. France Dermatological Drugs Market Forecast 2020-2030
  • 10.4. U.K.
    • 10.4.1. The Impact of Brexit On the Dermatological Drugs
    • 10.4.2. Pricing and Reimbursement
    • 10.4.3. New Regulatory Body and Clinical Trials
    • 10.4.4. Patent Protection
    • 10.4.5. Research and Funding
    • 10.4.6. U.K. Dermatological Drugs Market Forecast 2020-2030
  • 10.5. Italy
    • 10.5.1. Italy Dermatological Drugs Market Forecast 2020-2030
  • 10.6. Spain Dermatological Drugs Market Forecast 2020-2030
  • 10.7. Rest of Europe Dermatological Drugs Market Forecast 2020-2030
    • 10.7.1. Russia
      • 10.7.1.1. Pharma2020. Strategy - Healthcare and Industry Reform

11. Asia-Pacific Dermatological Drugs Market 2020-2030

  • 11.1. China
    • 11.1.1. Expansion of Healthcare Coverage and Reimbursement in China
    • 11.1.2. Improving Public Perception of Dermatology in China
    • 11.1.3. Price Controls and the Anhui Model
    • 11.1.4. Chinese Dermatological Drugs Market Forecast 2020-2030
  • 11.2. Japan Dermatological Drugs Market: Trends and Developments
    • 11.2.1. The Cost of Treatment in Japan
    • 11.2.2. Japanese Pharmaceutical Industry Regulatory Reform
    • 11.2.3. Japanese Dermatological Drugs Market Forecast 2020-2030
  • 11.3. India
    • 11.3.1. The Effects of the Drug Prices Control Order of 2013
    • 11.3.2. India's Expansion of Healthcare Provision
    • 11.3.3. Revised Biosimilar Guidelines
    • 11.3.4. Indian Dermatological Drugs Market Forecast 2020-2030
  • 11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments

12. Latin America Dermatological Drugs Market 2020-2030

  • 12.1. Brazil
    • 12.1.1. The Growth in Brazil's Healthcare Landscape
    • 12.1.2. Clearer Access to Medicines in Brazil
    • 12.1.3. Brazil Dermatological Drugs Market Forecast 2020-2030
  • 12.2. Mexico Dermatological Drugs Market: Trends and
  • 12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments

13. Middle East & Africa Dermatological Drugs Market 2020-2030

  • 13.1. Saudi Arabia Dermatological Drugs Market Forecast 2020-2030
  • 13.2. South Africa Dermatological Drugs Market Forecast 2020-2030
  • 13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2020-2030

14. Leading Companies in the Dermatological Drugs Market

  • 14.1. Galderma (Nestle Skin Health S.A.)
    • 14.1.1. Galderma: Dermatological Drugs Product Portfolio
    • 14.1.2. Financial Overview
    • 14.1.3. Recent Transactions Summary
  • 14.2. Johnson & Johnson
    • 14.2.1. Johnson & Johnson: Dermatological Drugs Product Portfolio
    • 14.2.2. Financial Overview
      • 14.2.2.1. Pipeline, 2019
    • 14.2.3. Recent Transactions Summary
  • 14.3. GlaxoSmithKline plc
    • 14.3.1. GlaxoSmithKline plc: Dermatological Drugs Portfolio
    • 14.3.2. GlaxoSmithKline plc: Financial Overview
    • 14.3.3. GlaxoSmithKline plc: Recent Transactions Summary
  • 14.4. Pfizer, Inc.
    • 14.4.1. Pfizer, Inc.: Dermatological Drugs Portfolio
    • 14.4.2. Pfizer, Inc.: Financial Overview
    • 14.4.3. Pfizer, Inc.: Recent Developments
    • 14.4.4. Pfizer: Dermatological Drugs Development Pipeline, 2019
  • 14.5.LEO Pharma A/S
    • 14.5.1. LEO Pharma A/S.: Dermatological Drugs Product Portfolio
    • 14.5.2. Financial Overview
    • 14.5.3. Recent Transactions Summary
  • 14.6. AbbVie Inc.
    • 14.6.1. AbbVie Inc.: Dermatological Drugs Product Portfolio
    • 14.6.2. Financial Overview
    • 14.6.3. Recent Transactions Summary
  • 14.7. Novartis AG
    • 14.7.1. Novartis: Dermatological Drugs Portfolio
    • 14.7.2. Novartis: Financial Overview
    • 14.7.3. Novartis: Recent Developments
  • 14.8. Amgen, Inc.
    • 14.8.1. Amgen, Inc.: Dermatological drugs Portfolio
    • 14.8.2. Financial Overview
    • 14.8.3. Recent Transactions Summary
  • 14.9. Merck & Co., Inc.
    • 14.9.1. Merck & Co., Inc.: Dermatological Drugs Portfolio
    • 14.9.2. Merck & Co., Inc.: Financial Overview
    • 14.9.3. Merck & Co., Inc.: Recent Transactions Summary
  • 14.10. Bayer AG
    • 14.10.1. Bayer AG: Dermatological Drugs Portfolio
    • 14.10.2. Bayer AG: Financial Overview
    • 14.10.3. Bayer AG: Recent Transactions Summary
  • 14.11. Celgene Corporation
    • 14.11.1. Celgene Corporation: Dermatological Drugs Product Portfolio
    • 14.11.2. Celgene Corporation: Financial Overview
    • 14.11.3. Celgene Corporation: Recent Transactions Summary
  • 14.12. Bausch Health Companies Inc.
    • 14.12.1. Bausch Health Companies Inc.: Dermatological Drugs Product Portfolio
    • 14.12.2. Bausch Health Companies Inc.: Dermatological Drugs Product Pipeline
    • 14.12.3. Bausch Health Companies Inc.: Financial Overview
    • 14.12.4. Bausch Health Companies Inc.: Recent Developments
  • 14.13. Bristol-Myers Squibb Company
    • 14.13.1. Bristol-Myers Squibb Company: Dermatological Drugs Product Portfolio
    • 14.13.2. Bristol-Myers Squibb Company: Dermatological Drugs Product Pipeline
    • 14.13.3. Bristol-Myers Squibb Company: Financial Overview
    • 14.13.4. Bristol-Myers Squibb Company: Recent Transactions Summary
  • 14.14. Allergan plc
    • 14.14.1. Allergan plc: Dermatological Drugs Product Portfolio
    • 14.14.2. Allergan plc: Financial Overview
    • 14.14.3. Allergan plc: Recent Transactions Summary
  • 14.15. Eli Lilly and Company
    • 14.15.1. Eli Lilly and Company: Dermatological Drugs Product Portfolio
    • 14.15.2. Eli Lilly and Company: Financial Overview
    • 14.15.3. Eli Lilly and Company: Recent Transactions Summary

15. Dermatological Drugs: Research and Development Pipeline, 2020-2030

  • 15.1. Innovative Products Currently in Development Will Drive Growth
    • 15.1.1. New Technology in R&D Pipeline Activities
      • 15.1.1.1. Reformulation
      • 15.1.1.2. Combination Treatments
      • 15.1.1.3. New Mechanisms and Drug Delivery Technologies
      • 15.1.1.4. Potential Market Entrants
  • 15.2. Psoriasis Drugs Development Pipeline, 2019
    • 15.2.1. Psoriasis Drugs in Phase 3 Development or
      • 15.2.1.2. CF101 (Piclidenoson) - Can-Fite BioPharma
    • 15.2.2. Psoriasis Drugs in Phase 2. Development
      • 15.2.2.1. LY3009104 (baricitinib) - Incyte/ Eli Lilly
      • 15.2.2.2. PH-10 (Rose Bengal) - Provectus
    • 15.2.3. Psoriasis Drugs in Phase 1 and Pre-Clinical
  • 15.3. Skin Infection Drugs Development Pipeline, 2019
    • 15.3.1. Drugs in Phase 3 Development for Skin Infections
      • 15.3.1.1. Baxdela (delafloxacin) - Melinta Pharmaceuticals
      • 15.3.1.2. NB-001 - NanoBio Corporation
      • 15.3.1.3. Luliconazole - Topica Pharmaceuticals
    • 15.3.2. Drugs in Phase 2 Development for Skin Infections
    • 15.3.3. Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
  • 15.4. Acne Drugs Development Pipeline, 2019
    • 15.4.1. Drugs in Phase 3 Development for Acne
      • 15.4.1.2. Visonac (photodynamic therapy) - Photocure
    • 15.4.2. Drugs in Phase 2 Development for Acne
    • 15.4.3. Drugs in Phase 1 and Pre-Clinical Development for Acne
    • 15.4.4. A Possible Vaccine for Acne
  • 15.5. Dermatitis Drugs Development Pipeline, 2019
    • 15.5.1. Drugs in Phase 3 Development for Dermatitis
      • 15.5.1.1. Toctino (alitretinoin) - GSK
      • 15.5.1.2. Dermadexin and Pruridexin (P3CGM) - Cipher
      • 15.5.1.3. Dexeryl Cream (glycerol/paraffin emollient) - Pierre
      • 15.5.1.4. REGN668/SAR231893 (dupilumab) -
    • 15.5.2. Drugs in Phase 2 Development for Dermatitis
    • 15.5.3. Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
  • 15.6. Other Dermatological Drugs Development Pipeline, 2019
    • 15.6.1. Other Dermatological Drugs: Filed or Recently
      • 15.6.1.1. Actikerall (fluorouracil/salicylic acid) - Almirall
      • 15.6.1.2. Ameluz (5-ALA photodynamic therapy) - Biofrontera
      • 15.6.1.3. Mirvaso (brimonidine) - Galderma
      • 15.6.1.4. Picato (ingenol mebutate) - LEO Pharma
      • 15.6.1.5. Xolair (omalizumab) - Novartis/ Roche
    • 15.6.2. Other Dermatological Drugs: Phase 3 Pipeline
      • 15.6.2.1. CD5024 (ivermectin) - Galderma
      • 15.6.2.2. SR-T100 gel (Solanum incanum extract) - G&E
    • 15.6.3. Other Dermatological Drugs: Phase 2 Pipeline

16. Qualitative Analysis of the Dermatological Drugs Market, 2020-2030

  • 16.1. Market Factors Influencing Dermatological Drugs
  • 16.2. SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030
    • 16.2.1. Strengths
      • 16.2.1.1. The High Unmet Clinical Need in Dermatology
      • 16.2.1.2. A Healthy Pipeline of Development-Stage Products
      • 16.2.1.3. Strong Industry-Physician Relationships
    • 16.2.2. Weaknesses
      • 16.2.2.1. Limited Efficacy and Adverse Effects May Impact
      • 16.2.2.2. Patient Adherence - A Major Challenge to
      • 16.2.2.3. Impending Patent Expiries and the Challenges
    • 16.2.3. Opportunities
      • 16.2.3.1. The High-Growth Sectors in Dermatology
      • 16.2.3.2. Personalised Dermatology: Technological Advances in Genomics
      • 16.2.3.3. Advances in Topical Drug Delivery Methods Offers
      • 16.2.3.4. Consolidation within Dermatology - Opportunity for Synergistic Growth?
    • 16.2.4. Threats
      • 16.2.4.1. Uncertainty Surrounding Reimbursement and
      • 16.2.4.2. The Rising Cost of Research and Development
      • 16.2.4.3. Downward Pressures on Drug Prices
  • 16.3. Porter's Five Force Analysis of the Global Dermatological Drugs Market, 2020-2030
    • 16.3.1. Threat of New Entrants
    • 16.3.2. Threat of Substitutes
    • 16.3.3. Rivalry among Competitors
    • 16.3.4. Power of Buyers
    • 16.3.5. Power of Suppliers

17. Conclusions

  • 17.1. Overview of Current Market Conditions and Market Forecast, 2020-2030
  • 17.2. Leading Sectors in Dermatological Drugs in 2019
  • 17.3. Leading Regions in the Dermatological Drugs Market in 2019
  • 17.4. Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2020-2030
  • 17.5. What Does the Future Hold for Dermatological Drugs?

Appendices

  • Associated Visiongain Reports
  • Global OTC Pharmaceutical Market Forecast 2020-2030
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Clinical Trial Phases, 2019
  • Table 3.1: Global Dermatological Drugs Market Indication: Revenue ($bn), and Market Share (%), 2019
  • Table 3.2: Global Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 3.3: Global Dermatological Drugs Market Indication: CAGR (%), 2020-2025, 2025-2030, 2020-2030
  • Table 4.1: Global Psoriasis Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
  • Table 4.2: Global Psoriasis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.3: Global Psoriasis Drugs Market by Drugs: Market Share (%), 2020-2025, 2025-2030, 2020-2030
  • Table 4.4: Global Humira Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 4.5: Global Humira Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.6: Global Stelara Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 4.7: Global Stelara Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.8: Global Enbrel Market Forecast: Revenues ($Bn) AGR (%), 2009-2017
  • Table 4.9: Global Enbrel Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.10: Global Remicade Market Forecast: Revenues ($bn) AGR (%), 2009-2017
  • Table 4.11: Global Remicade Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.12: Global Taltz Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.13: Global Otezla Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.14: Global Cosentyx Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 4.15: Global Others Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030
  • Table 5.1: Global Skin Infection Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
  • Table 5.2: Skin Infection Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 5.3: Global Skin Infection Drugs Market by Drugs: Market Share (%), 2019, 2025, & 2030
  • Table 5.4: Global Cubicin Market Forecast: Revenue ($bn) AGR & CAGR (%), 2019-2030
  • Table 5.5: Global Zyvox Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 5.6: Global Zyvox Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 5.7: Global Canesten Market Forecast: Revenues ($bn) AGR (%), 2011-2017
  • Table 5.8: Global Canesten Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 5.9: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 5.10: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 5.11: Global Sivexto Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 5.12: Global Lamisil Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030
  • Table 5.13: Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.1: Global Acne Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
  • Table 6.2: Global Acne Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 6.3: Global Acne Drugs Market by Drugs: Market Share (%), 2019, 2025, 2030
  • Table 6.4: Global Epiduo Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.5: Global Solodyn Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.6: Global Claravis Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.7: Global Aczone Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.8: Global Retin-A Micro Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.9: Global Absorica/ Epirus Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.10: Global Ziana Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.11: Global Acanya/Onexton Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030
  • Table 6.12: Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 7.1: Global Dermatitis Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
  • Table 7.2: Global Dermatitis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 7.3: Global Dermatitis Drugs Market by Drugs: Market Share (%), 2019, 2025, 2030
  • Table 7.4: Global Bepanthen/ Bepanthol Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 7.5: Global Elocon Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 7.6: Global Protopic Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 7.7: Global Dermovate Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 7.8: Others Dermatitis Drugs Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
  • Table 8.1: Global Dermatological Drugs Market by Region: Revenue ($bn), 2019 and 2030
  • Table 8.2: Global Dermatological Drugs Market Forecast, by Region: Revenues ($ bn), AGR (%), CAGR (%), 2019-2030
  • Table 8.3: Global Dermatological Drugs Market by Region: Market Share (%), 2019, 2025, & 2030
  • Table 8.4: Global Dermatological Drugs Market by Region: Market Share (%), 2020, 2025, & 2030
  • Table 9.1: North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 9.2: North America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 9.3: U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 9.4: Canada Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 10.1: Global Dermatological Drugs Market by Country/Sub-region: Revenue ($bn) and Market Share (%), 2019
  • Table 10.2: Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 10.3: Europe Dermatological Drugs Market Forecast, By Country: Revenues ($ bn), AGR (%), CAGR (%), 2019-2030
  • Table 10.4: Europe Dermatological Drugs Market by Country/Sub-region: Market Share (%) 2019, 2025, & 2030
  • Table 10.5: Germany Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 10.6: France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 10.7: U.K. Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 10.8: Italy Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 10.9: Spain Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 10.10: Rest of Europe Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 11.1: Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 11.2: Asia-Pacific Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 11.3: China Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 11.4: Japan Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 11.5: India Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 11.6: Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2019-2030 ($ bn, AGR %, CAGR %)
  • Table 12.1: Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 12.2: Latin America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 12.3: Brazil Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 12.4: Mexico Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 12.5: Rest of Latin America Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 13.1: Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 13.2: Middle East & Africa (MEA) Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 13.3: Saudi Arabia Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
  • Table 13.4: South Africa Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 13.5: Rest of MEA Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
  • Table 14.1: Galderma: Overview, 2019
  • Table 14.2: Johnson & Johnson: Overview, 2019
  • Table 14.3: Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
  • Table 14.4: GlaxoSmithKline plc: Overview, 2019
  • Table 14.5: GlaxoSmithKline plc: Revenue ($m), 2014-2018
  • Table 14.6: GlaxoSmithKline: Dermatological Drugs Pipeline, 2019
  • Table 14.7: Pfizer, Inc.: Overview, 2019
  • Table 14.8: Pfizer, Inc.: Revenue ($m), 2015-2018
  • Table 14.9: LEO Pharma A/S: Overview, 2019
  • Table 14.10: LEO Pharma A/S: Revenue ($m), AGR (%), 2014-2018
  • Table 14.11: AbbVie Inc.: Overview, 2019
  • Table 14.12: AbbVie Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 14.13: Novartis: Overview, 2019
  • Table 14.14: Novartis: Revenue ($m), AGR (%), 2014-2018
  • Table 14.15: Amgen, Inc.: Overview, 2019
  • Table 14.16: Amgen, Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 14.17: Merck & Co., Inc.: Overview, 2019
  • Table 14.18: Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 14.19: Bayer AG: Overview, 2019
  • Table 14.20: Bayer AG: Revenue ($m), AGR (%), 2014-2018
  • Table 14.21: Celgene Corporation: Overview, 2019
  • Table 14.22: Celgene Corporation: Revenue ($m), AGR (%), 2014-2018
  • Table 14.23: Bausch Health Companies Inc.: Overview, 2019
  • Table 14.24: Bausch Health Companies Inc.: Revenue ($m), AGR (%), 2014-2018
  • Table 14.25: Bristol-Myers Squibb Company: Overview, 2019
  • Table 14.26: Bristol-Myers Squibb Company: Revenue ($m), AGR (%), 2014-2018
  • Table 14.27: AbbVie Inc.: Overview, 2019
  • Table 14.28: Allergan plc: Revenue ($m), AGR (%), 2014-2018
  • Table 14.29: Eli Lilly and Company: Overview, 2019
  • Table 14.30: Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018
  • Table 15.1: Psoriasis Drugs Pipeline: Phase 3 Drugs, 2019
  • Table 15.2: Psoriasis Drugs Pipeline: Phase 2 Drugs, 2018
  • Table 15.3: Psoriasis Drugs Pipeline: Phase 1 Drugs, 2018
  • Table 15.4: Skin Infections Drugs Pipeline: Phase 3 Drugs, 2019
  • Table 15.5: Skin Infections Drugs Pipeline: Phase 2 Drugs, 2019
  • Table 15.6: Acne Drugs Pipeline: Phase 3 Drugs, 2019
  • Table 15.7: Acne Drugs Pipeline: Phase 2 Drugs, 2019
  • Table 15.8: Dermatitis Drugs Pipeline: Phase 3 Drugs, 2019
  • Table 15.9: Dermatitis Drugs Pipeline: Phase 2 Drugs, 2019
  • Table 15.10: Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2019
  • Table 15.11: Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2019
  • Table 15.12: Dermatitis Drugs Pipeline: Phase 2 Drugs, 2019
  • Table 16.1: SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030
  • Table 17.1: Global Dermatological Drugs Market Forecast: Revenue ($bn), and CAGR (%), 2019, 2025 and 2030
  • Table 17.2: Global Dermatological Drugs Market by Indication: Revenue ($bn), and Market Share (%), 2019
  • Table 17.3: Global Dermatological Drugs Market by Region: Revenue ($bn), 2019, 2025, 2030
  • Table 17.4: Global Dermatological Drugs Market by Indication: Revenue ($Bn), 2020, 2025, 2030

List of Figures

  • Figure 1.1: Global Dermatological Drugs Market Segmentation Overview
  • Figure 2.1: Anatomy of Human Skin
  • Figure 3.1: Global Dermatological Drugs Market by Indication: Market Share (%), 2019
  • Figure 3.2: World Dermatological Drugs Market: Revenues ($bn), by Indication, 2019
  • Figure 3.3: Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2019-2030
  • Figure 3.4: The Global Dermatological Drugs Market Forecast by Indication: AGR (%), 2020-2025
  • Figure 3.5: The Global Dermatological Drugs Market Forecast by Indication: AGR (%), 2025-2030
  • Figure 3.6: The Global Dermatological Drugs Market Forecast by Indication: AGR (%) 2020-2030
  • Figure 3.7: Global Dermatological Drugs Market by Indication: Market Share (%), 2020
  • Figure 3.8: Global Dermatological Drugs Market by Indication: Market Share (%), 2025
  • Figure 3.9: Global Dermatological Drugs Market by Indication: Market Share (%), 2030
  • Figure 4.1: World Psoriasis Drugs Market: Revenues ($bn), by Drugs, 2019
  • Figure 4.2: Global Psoriasis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.3: Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2019
  • Figure 4.4: Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2025
  • Figure 4.5: Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2030
  • Figure 4.6: Global Humira Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 4.7: Global Humira Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.8: Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 4.9: Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.10: Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2009-2017
  • Figure 4.11: Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.12: Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2009-2017
  • Figure 4.13: Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.14: Global Taltz Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.15: Global Otezla Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.16: Global Cosentyx Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 4.17: Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.1 World Skin Infection Drugs Market: Revenues ($bn), by Drugs, 2019
  • Figure 5.2 Global Skin Infection Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.3 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2019
  • Figure 5.4 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2025
  • Figure 5.5 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2030
  • Figure 5.6 Global Cubicin Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.7 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 5.8 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.9 Global Canesten Market Forecast: Revenue ($bn) AGR (%), 2011-2017
  • Figure 5.10 Global Canesten Market Forecast: Revenue ($Bn) AGR (%), 2019-2030
  • Figure 5.11 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 5.12 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.13 Global Sivexto Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.14 Global Lamisil Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 5.15 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.1: World Acne Drugs Market: Revenues ($bn), by Drugs, 2019
  • Figure 6.2: Global Acne Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.3: The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2019
  • Figure 6.4: The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2025
  • Figure 6.5: The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2030
  • Figure 6.6: Global Epiduo Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.7: Global Solodyn Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.8: Global Claravis Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.9: Global Aczone Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.10: Global Retin-A Micro Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.11: Global Absorica/ Epirus Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.12: Global Ziana Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.13: Global Acanya/Onexton Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 6.14: Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 7.1: World Dermatitis Drugs Market: Revenues ($bn), by Drugs, 2019
  • Figure 7.2: Global Dermatitis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 7.3: The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2019
  • Figure 7.4: The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2025
  • Figure 7.5: The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2030
  • Figure 7.6: Global Bepanthen/ Bepanthol Market Forecast: Revenue ($bn), AGR (%), 2019-2030
  • Figure 7.7: Global Elocon Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 7.8: Global Protopic Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 7.9: Global Dermovate Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 7.10: Global Other Dermatitis Market Forecast: Revenue ($bn) AGR (%), 2019-2030
  • Figure 8.1: World Dermatological Drugs Market: Revenues ($bn) by Region, 2019
  • Figure 8.2: World Dermatological Drugs Market: Revenues ($bn) by Region, 2030
  • Figure 8.3: Global Dermatological Drugs Market Forecast By Region: Revenue ($bn), 2019-2030
  • Figure 8.4: World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2020
  • Figure 8.5: World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2025
  • Figure 8.6: World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2030
  • Figure 9.1: North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 9.2: North America Dermatological Drugs Market: Market Shares (%) by Country, 2019
  • Figure 9.3: North America Dermatological Drugs Market: Market Shares (%) by Country, 2025
  • Figure 9.4: North America Dermatological Drugs Market: Market Shares (%) by Country, 2030
  • Figure 9.5: U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 9.6: Canada Dermatological Drugs Market Forecast: Revenues ($ Bn), AGR (%), 2019-2030
  • Figure 10.1: Europe Dermatological Drugs Market: Revenues ($bn) by Country/Sub-region, 2019
  • Figure 10.2: Europe Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
  • Figure 10.3: Europe Dermatological Drugs Market: Market Shares (%) by Regional Market, 2019
  • Figure 10.4: Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2025
  • Figure 10.5: Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2030
  • Figure 10.6:: Germany Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 10.7: France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 10.8: U.K. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 10.9: Italy Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 10.10: Spain Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 10.11: Rest of Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 11.1: Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 11.2: Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2019
  • Figure 11.3: Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2025
  • Figure 11.4: Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2030
  • Figure 11.5: China Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
  • Figure 11.6: Japan Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
  • Figure 11.7: India Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 11.8: Rest of Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 12.1: Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 12.2: Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2019
  • Figure 12.3: Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2025
  • Figure 12.4: Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2030
  • Figure 12.5: Brazil Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
  • Figure 12.6: Mexico Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
  • Figure 12.7: Rest of Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 13.1: Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 13.2: Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2019
  • Figure 13.3: Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2025
  • Figure 13.4: Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2030
  • Figure 13.5: Saudi Arabia Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 13.6: South Africa Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 13.7: Rest of MEA Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
  • Figure 14.1: Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.2: Johnson & Johnson: Business Segment Revenue Share (%), 2018
  • Figure 14.3: Johnson & Johnson: Region Revenue Share (%), 2018
  • Figure 14.4: GlaxoSmithKline plc: Revenue ($m), 2014-2018
  • Figure 14.5: GlaxoSmithKline plc: Business Segment Revenue Share (%), 2018
  • Figure 14.6: GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2018
  • Figure 14.7: GlaxoSmithKline plc: by Region Revenue Share (%), 2018
  • Figure 14.8: Pfizer, Inc.: Revenue ($bn), Net Income (Sbn), R&D Investment ($bn), 2019-2018
  • Figure 14.9: Pfizer, Inc.: Business Segment Revenue Share (%), 2018
  • Figure 14.10: Pfizer, Inc.: National Revenue Share (%), 2018
  • Figure 14.11: LEO Pharma A/S : Revenue ($m), AGR (%), 2014-2018
  • Figure 14.12: LEO Pharma A/S: Therapeutic Area Revenue Share (%), 2018
  • Figure 14.13: LEO Pharma A/S: Region Revenue Share (%), 2018
  • Figure 14.14: AbbVie Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.15: AbbVie Inc.: Regional Segment Revenue Share (%), 2018
  • Figure 14.16: Novartis: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.17: Novartis: Revenue, by Division, Share (%), 2018
  • Figure 14.18: Novartis: Revenue, by Region, Share (%), 2018
  • Figure 14.19: Amgen, Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.20: Amgen, Inc.: Revenue, by Division, Share (%), 2018
  • Figure 14.21: Amgen, Inc.: Revenue, by Region, Share (%), 2019
  • Figure 14.22: Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.23: Merck & Co., Inc.: Business Segment Revenue Share (%), 2018
  • Figure 14.24: Merck & Co., Inc.: Region Revenue Share (%), 2018
  • Figure 14.25: Bayer AG: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.26: Bayer AG: Business Segment Revenue Share (%), 2018
  • Figure 14.27: Bayer AG: Region Revenue Share (%), 2018
  • Figure 14.28: Celgene Corporation: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.29: Celgene Corporation: Regional Segment Revenue Share (%), 2018
  • Figure 14.30: Bausch Health Companies Inc.: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.31: Bausch Health Companies Inc.: Regional Segment Revenue Share (%), 2018
  • Figure 14.32: Bristol-Myers Squibb Company: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.33: Bristol-Myers Squibb Company: Regional Segment Revenue Share (%), 2018
  • Figure 14.34: Allergan plc: Revenue ($m), AGR (%), 2014-2018
  • Figure 14.35: Allergan plc: Regional Segment Revenue Share (%), 2018
  • Figure 14.36: Eli Lilly and Company: Revenue, Net Income, and R&D Investment ($m), 2014-2018
  • Figure 14.37: Eli Lilly and Company: Regional Segment Revenue Share (%), 2018
  • Figure 16.1: Porter's Five Force Analysis
  • Figure 17.1: Global Dermatological Drugs Market Forecast: Revenue ($bn) 2017, 2025, 2030
  • Figure 17.2: World Dermatological Drugs Market: Revenues ($bn), by Indication, 2019
  • Figure 17.3: The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2019, 2025, 2030
  • Figure 17.4: The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2019, 2025, 2030

List of Companies and Organizations Mentioned in the Report:

  • Abbott
  • AbbVie
  • Actavis
  • AET BioTech
  • Alkem Laboratories
  • Allergan
  • Almirall
  • Amgen
  • Anacor
  • Ascend Therapeutics
  • Astellas
  • Aurovindo
  • Barr Labs
  • Bayer
  • Betta Pharmaceuticals
  • Biocon/Mylan
  • Biofrontera
  • Biogen
  • Biovail Laboratories
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Brazilian Society of Dermatology
  • Cadila Healthcare
  • Calico
  • Can-Fite BioPharma
  • Cassiopea SpA
  • Celgene
  • Celltrion
  • Cempra
  • Cipher Pharmaceuticals
  • Cipla
  • Colorescience
  • Cubist Pharmaceuticals
  • Cutanea Life Sciences
  • Dow Pharmaceuticals Science
  • Dr Reddy's
  • Durata Therapeutics
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • FibroTx
  • Food and Drug Association (FDA)
  • Foamix
  • Fougera
  • Fujifilm
  • Galapagos NV
  • G&E Herbal Biotechnology
  • Galderma
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Heritage
  • Impax
  • Incyte
  • International Health Partners
  • Janssen Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • L'Oreal
  • LEO Pharma
  • Lupin
  • Maruho
  • Mayne Pharma
  • Medicis
  • Medison Pharma
  • Melinta Pharmaceuticals
  • Merck
  • Merz Pharmaceuticals
  • Mitsubishi Tanabe
  • MorphoSys
  • Mylan
  • NanoBio Corporation
  • National Psoriasis Foundation (NPF)
  • NeoStrata Compnay Inc
  • Nestle Skin Health
  • Novan
  • Novartis
  • Perriogo
  • Pfizer
  • PharmaPraxis
  • Photocure
  • Pierre Fabre
  • Provectus Biopharmaceuticals
  • QLT Inc
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Schering-Plough
  • Shanghai CP Buojian Pharmaceutical
  • Sidmak Labs
  • Sol-Gel Technologies Ltd
  • Sun Pharma
  • Sunovion
  • Takeda
  • Tanabe
  • Tanja Todberg
  • Taro Pharmaceuticals
  • Teva
  • Thesan Pharmaceuticals Inc
  • Topica Pharmaceuticals
  • UCB
  • Valeant
  • Vical
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Xenon Pharmaceuticals
  • Ziarco Group Limited
  • Zydus